论文部分内容阅读
目的:研究分析诺和锐30对于治疗初诊2型糖尿病的临床价值。方法:选取本院自2012年6月-2014年6月间曾收治本院的60例初诊2型糖尿病患者作为本次的研究观察对象。按照随机分组对照的原则将其随机分为对照组和治疗组,对照组的患者采用维格列汀治疗,而治疗组的患者则采用维格列汀联合诺和锐30的方法进行治疗。后对比观察两组患者的临床治疗效果。结果:研究结果显示,治疗后,对照组患者的空腹血糖以及餐后血糖均较治疗组患者高,差异具有统计学意义,P<0.05。结论:研究表明,诺和锐30对于治疗初诊2型糖尿病患者具有显著的临床疗效。
Objective: To study the clinical value of Novo-Rui 30 in the treatment of newly diagnosed type 2 diabetes mellitus. Methods: Sixty cases of newly diagnosed type 2 diabetes patients admitted to our hospital from June 2012 to June 2014 were selected as the study objects. According to the principle of randomized grouping control, they were randomly divided into control group and treatment group. Patients in control group were treated with Vildagliptin, while patients in treatment group were treated with Vildagliptin and Novo-Rui 30. After comparing the two groups of patients for clinical treatment. Results: The results showed that after treatment, the fasting blood glucose and postprandial blood glucose in the control group were significantly higher than those in the treatment group, the difference was statistically significant (P <0.05). Conclusion: The study shows that Novo Rui 30 for the treatment of newly diagnosed type 2 diabetes patients with significant clinical efficacy.